18th Winter Conference on Medicinal & Bioorganic Chemistry

Chief Scientific Officer

After graduating with a degree in Mathematics in 1995, Ed joined GlaxoWellcome as part of a pioneering team building predictive pharmaceutical tools.

He developed the first graphical user interfaces for working with predictive models, which were adopted globally within GlaxoWellcome.

He was a core member of the team which established the UK operation of Camitro in 2001 and remained with that company (now operating within BioFocus DPI following a merger and acquisition) until 2008.

During this time, he designed and built the StarDrop software and, in 2009, co-founded Optibrium.

LinkedIn

Principal Scientist

Kyle leverages 3D structure and ligand-based design, specifically through the BioPharmics platform, to accelerate lead discovery and optimisation. With a strong background in structural biology and computational chemistry, his expertise includes molecular docking, virtual screening, and integrating experimental data to drive rational drug design. 

Before joining Optibrium, Kyle held key research positions at Schrödinger and Xtal BioStructures. He earned his PhD in Biomedical Science from the University of South Florida, where his research focused on targeting bacterial resistance and cancer metastasis through structure-based approaches.

LinkedIn

Account Manager

Charlotte supports pharma and biotech discovery teams across the US, helping them make smarter, faster decisions with StarDrop, Cerella and BioPharmics. She works closely with medicinal chemists, computational chemists and DMPK scientists to connect the software to their project goals.

Charlotte’s career has spanned pharmaceutical sales, clinical services and scientific software. Before joining Optibrium, she held roles at TherapeuticsMD, Bioclinica and the Cambridge Crystallographic Data Centre (CCDC).

Charlotte holds a BA in Public Relations from Sonoma State University.

LinkedIn